A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Summary

This is a phase 1, randomized, single-center, 3-part, study to assess the safety, tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects and multiple doses of CC-92252 in adult subjects with psoriasis.

Timeline

Start

2018-07-24

Primary completion

2021-08-05

Completion

2021-08-05

Outcome

Outcome not reported

Stopped: “Did not meet progression criteria”

Drugs

Indications